- Home
- ALXO vs PLRX Comparison
ALXO vs PLRX Comparison
Compare ALXO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- PLRX
- Stock Information
- Founded
- ALXO 2015
- PLRX 2015
- Country
- ALXO United States
- PLRX United States
- Employees
- ALXO N/A
- PLRX N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- PLRX Health Care
- Exchange
- ALXO Nasdaq
- PLRX Nasdaq
- Market Cap
- ALXO 79.7M
- PLRX 93.3M
- IPO Year
- ALXO 2020
- PLRX 2020
- Fundamental
- Price
- ALXO $1.47
- PLRX $1.57
- Analyst Decision
- ALXO Strong Buy
- PLRX Hold
- Analyst Count
- ALXO 6
- PLRX 11
- Target Price
- ALXO $3.30
- PLRX $3.79
- AVG Volume (30 Days)
- ALXO 356.5K
- PLRX 707.4K
- Earning Date
- ALXO 11-07-2025
- PLRX 11-06-2025
- Dividend Yield
- ALXO N/A
- PLRX N/A
- EPS Growth
- ALXO N/A
- PLRX N/A
- EPS
- ALXO N/A
- PLRX N/A
- Revenue
- ALXO N/A
- PLRX N/A
- Revenue This Year
- ALXO N/A
- PLRX N/A
- Revenue Next Year
- ALXO N/A
- PLRX N/A
- P/E Ratio
- ALXO N/A
- PLRX N/A
- Revenue Growth
- ALXO N/A
- PLRX N/A
- 52 Week Low
- ALXO $0.40
- PLRX $1.10
- 52 Week High
- ALXO $2.27
- PLRX $15.80
- Technical
- Relative Strength Index (RSI)
- ALXO 49.39
- PLRX 46.13
- Support Level
- ALXO $1.29
- PLRX $1.48
- Resistance Level
- ALXO $1.56
- PLRX $1.82
- Average True Range (ATR)
- ALXO 0.18
- PLRX 0.12
- MACD
- ALXO 0.01
- PLRX -0.02
- Stochastic Oscillator
- ALXO 65.90
- PLRX 32.88
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.